辅助性T淋巴细胞17和调节性T淋巴细胞及其平衡改变与非酒精性脂肪性肝病的关系

高伟华; 葛宽雪; 向晓星

doi:10.3969/j.issn.1001-5256.2018.06.046

辅助性T淋巴细胞17和调节性T淋巴细胞及其平衡改变与非酒精性脂肪性肝病的关系

DOI: 10.3969/j.issn.1001-5256.2018.06.046

1. 扬州大学医学院
2. 江苏省苏北人民医院

详细信息

中图分类号: R575.5
计量
- 文章访问数: 266
- HTML全文浏览量: 36
- PDF下载量: 69
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-28
- 出版日期: 2018-06-20

Association of Th17 cells, regulatory T cells, and their imbalance with nonalcoholic fatty liver disease

Yangzhou University Medical College

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)与胰岛素抵抗、遗传易感性密切相关,是危害人类健康的慢性肝病之一。辅助性T淋巴细胞(Th17)、调节性T淋巴细胞(Treg)在一定条件下,两者存在相互转化的关系,维持免疫稳态。近年来,有关Th17与Treg及其平衡参与肝脏疾病的发生发展的研究也越来越深入。Th17与Treg及其平衡可能成为NAFLD治疗的新靶点,综述了Th17细胞、Treg细胞与NAFLD的关系及二者平衡改变在NAFLD疾病发生发展中最新的研究进展。
- 非酒精性脂肪性肝病 /
- T淋巴细胞,辅助诱导 /
- T淋巴细胞,调节性 /
- 综述
Abstract: Nonalcoholic fatty liver disease (NAFLD) is closely associated with insulin resistance and genetic susceptibility and is one of the chronic liver diseases that threaten human health. Under certain conditions, Th17 cells and regulatory T (Treg) cells can be transformed to each other to maintain immune homeostasis. In recent years, more and more studies have been performed on the involvement of Th17 and Treg cells in the development and progression of liver diseases. Th17 cells, Treg cells, and their balance may become the new targets for the treatment of NAFLD. This article reviews the latest research advances in the association of Th17 and Treg cells with NAFLD and the role of Th17/Treg balance in the development and progression of NAFLD.
- nonalcoholic fatty liver disease /
- T-lymphocytes, helper-inducer /
- T-lymphocytes, regulatory /
- review

HTML全文

参考文献(49)

[1]TORRES DM, WILLIAMS CD, HARRISON SA.Features, diagnosis, and treatment of nonalcoholic fatty liver disease[J].Clin Gastroenterol Hepatol, 2012, 10 (8) :837-858.

[2]VUPPALANCHI R, CHALASANI N.Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis:Sekcted practical issues in their evaluatin and management[J].Hepalology, 2009, 49 (1) :306-317.

[3]KALISH BT, LE HD, GURA KM, et al.A metabolomic analysis of two intravenous lipid emulsions in a murine model[J].PLo S One, 2013, 8 (4) :e59653.

[4]MIURA K, KODAMA Y, INOKUCHI S, et al.Toll-like receptor 9promotes steatohepatitis by induction of interleukin-1beta in mice[J].Gastroenterology, 2010, 139 (1) :323-334.

[5]WINER S, CHAN Y, PALTSER G, et al.Normalization of obesity-associated insulin resistance through immunotherapy[J].Nat Med, 2009, 15 (8) :921-929.

[6]LAURENCE A, TATO CM, DAVIDSON TS, et al.Interleukin-2signaling via STAT5 constrains T helper 17 cell generation[J].Immunity, 2007, 26 (3) :371-381.

[7]YANG XO, PANOPOULOS AD, NURIEVA R, et al.STAT3 regulates cytokine mediated generation of inflammatory helper T cells[J].J Bio Chem, 2007, 282 (13) :9358-9363.

[8]NALBANT A, ESKIER D.Genes associated with T helper 17 cell differentiation and function[J].Front Biosci (Elite Ed) , 2016, 8:427-435.

[9]ROCHA AM, SOUZA C, ROCHA GA, et al.The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia[J].Haematologica, 2011, 96 (10) :1560-1564.

[10]VONGHIA L, RUYSSERS N, SCHRIJVERS D, et al.CD4+RORγt++and Tregs in a mouse model of diet-induced nonalcoholic steatohepatitis[J].Mediators Inflamm, 2015, 2015:239623.

[11]ROLLA S, ALCHERA E, IMARISIO C, et al.The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice[J].Clin Sci (Lond) , 2016, 130 (3) :193-203.

[12]TANG Y, BIAN Z, ZHAO L, et al.Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease[J].Clin Exp Immunol, 2011, 166 (2) :281-290.

[13]ZHANG JY, ZHANG Z, LIN F, et al.Interleukin-17-producing CD4 (+) T cells increase with severity of liver damage in patients with chronic hepatitis B[J].Hepatology, 2010, 51 (1) :81-91.

[14]WRIGHT JF, BENNETT F, LI B, et al.The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex[J].J Immunol, 2008, 181 (4) :2799-2805.

[15]GAFFEN SL.An overview of IL-17 function and signaling[J].Cytokine, 2008, 43 (4) :402-407.

[16]SHEN F, GAFFEN SL.Structure-function relationships in the IL-17receptor:Implications for signal transduction and therapy[J].Cytokine, 2008, 41 (2) :92-104.

[17]MENG F, WANG K, AOYAMA T, et al.Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice[J].Gastroenterology, 2012, 143 (3) :765-776.

[18]XU R, TAO A, ZHANG S, et al.Neutralization of interleukin-17attenuates high fat diet-induced non-alcoholic fatty liver disease in mice[J].Acta Biochim Biophys Sin (Shanghai) , 2013, 45 (9) :726-733.

[19]HAREY IT, STANIEWICZ TE, GIES DA, et al.IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice[J].Hepatology, 2014, 59 (5) :1830-1839.

[20]GIES DA, MORENO-FERNANME, STTANKIEWICZ TE.Regulation of inflammation by IL-17A and IL-17F modulates non-alcoholic fatty liver disease pathogenesis[J].PLo S One, 2016, 11 (2) :e0149783.

[21]GOMES AL, TEIEIRO A, BUREN S, et al.Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma[J].Cancer Cell, 2016, 30 (1) :161-175.

[22]SABAT R, OUYANG W, WOLK K.Therapeutic opportunities of the IL-22-IL-22R1 system[J].Nat Rev Drug Discov, 2014, 13 (1) :21-38.

[23]COBEIGH MA, ROBEK MD.Protective and pathological properties of IL-22 in liver disease:Implications for viral hepatitis[J].Am J Pathol, 2013, 182 (1) :21-28.

[24]RADAEVA S, SUN R, PAN HN, et al.Interleukin 22 (IL-22) plays protective role in T cell-mediated murine hepatitis:IL-22is a survival factor for hepatocytes via STAT3 activation[J].Hepatology, 2004, 39 (5) :1332-1342.

[25]KI SH, PARK O, ZHENG M, et al.Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding:Role of signal transducer and activator of transcription[J].Hepatology, 2010, 52 (4) :1291-1300.

[26]YANG L, ZHANG Y, WANG L, et al.Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22[J].J Hepatol, 2010, 53 (2) :339-347.

[27]ZHAO J, ZHANG Z, LUAN Y, et al.Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment[J].Hepatology, 2014, 59 (4) :1331-1342.

[28]LI MO, RUDENSY AY.T cell receptor signalling in the control of regulatory T cell differentiation and function[J].Nat Rev Immunol, 2016, 16 (4) :220-233.

[29]LANE N, ROBINS RA, CORNE J, et al.Regulation in chronic obstructive pulmonary disease:the role of regulatory T-cells and Th17cells[J].Clin Sci (Lond) , 2010, 119 (2) :75-86.

[30]DENNIS KL, BLANTNER NR, GOUNARI F, et al.Current status of interleukin-10 and regulatory-T cells in cancer[J].Curr Opin Oncol, 2013, 25 (6) :637-645.

[31]MA C, KESARWALA AH, EGGERT T, et al.NAFLD causes selective CD4 (+) T lymphocyte loss and promotes hepatocarcinogenesis[J].Nature, 2016, 531 (7593) :253-257.

[32]MA X, HUA J, MOHAMOOD AR, et al.A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury[J].Hepatology, 2007, 46 (5) :1519-1529.

[33]RAU M, SCHILING AK, MEERTENS J, et al.Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver[J].J Immunol, 2016, 196 (1) :97-105.

[34]LALAZAR G, MIZRAHI M, TURGEMAN I, et al.Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cellinduction, and alleviates insulin resistance:Results of a phase IIa blinded placebo-controlled trial[J].J Clin Immunol, 2015, 35 (4) :399-407.

[35]SAPAN HB, PATURUI I, JUSUF I, et al.Pattern of cytokine (IL-6 and IL-10) level as inflammation and antiinflammation mediator of multiple organ dysfunction syndrome (MODS) in polytrauma[J].Int J Burns Trauma, 2016, 6 (2) :37-43.

[36]HU D, WAN L, CHEN M, et al.Essential role of IL-10/STAT3in chronic stress-induced immune suppression[J].Brain Behav Immun, 2014, 36:118-127.

[37]STAPLES KJ, SMALLIE T, WILLIAMS LM, et al.IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcriptionfactor Stat 3[J].J Immunol, 2007, 178 (8) :4779-4785.

[38] CHAUDHRY A, SAMSTEIN RM, TREUTING P, et al.Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation[J].Immunity, 2011, 34 (4) :566-578.

[39]GU Y, YANG J, OUYANG X, et al.Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells[J].Eur J Immunol, 2008, 38 (7) :1807-1813.

[40]ZHANG L, WANG XZ.Interleukin-10 and chronic liver disease[J].World J Gastroenterol, 2006, 12 (11) :1681-1685.

[41]ZAHRAN WE, SALAH EL-DIEN KA, KAMEL PG, et al.Efficacy of tumor necrosis factor and interleukin-10 analysis in the follow-up of nonalcoholic fatty liver disease progression[J].Indian J Clin Biochem, 2013, 28 (2) :141-146.

[42]PAREDES-TURRUBIARTE G, GONZAEZ-CHAVEZ A, PEREZTAMYO R, et al.Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients[J].Clin Exp Med, 2016, 16:193-202.

[43]VELDHOEN M, HOCING RJ, ATINS CJ, et al.TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells[J].Immunity, 2006, 24 (2) :179-189.

[44]SUN HQ, ZHANG JY, ZHANG H, et al.Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis[J].J Viral Hepat, 2012, 19 (6) :396-403.

[45]VONGHIA L, MAGRONE T, VERRIHEN A, et al.Peripheral and hepatic vein cytokine levels in correlation with non-alcoholic fatty liver disease (NAFLD) -related metabolic, histological, and haemodynamic features[J].PLo S One, 2015, 10 (11) :e0143380.

[46]MUCIDA D, HUSAIN MM, MUROI S, et al.Transcriptional reprogramming of mature CD4 helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes[J].Nat Immunol, 2013, 14 (3) :281-289.

[47]CHAUDHRY A, RUDRA D, TREUTING P, et al.CD4+regulatory T cells control TH17 responses in a Stat3-dependent manner[J].Science, 2009, 326 (5955) :986-991.

[48]HORIGUCHI N, LAFDIL F, MILLER AM, et al.Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice[J].Hepatology, 2010, 51 (5) :1724-1734.

[49]CHAUDHRY A, SAMSTEIN RM, TREUTING P, et al.Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation[J].Immunity, 2011, 34 (4) :566-578.

施引文献

资源附件(0)

访问统计